P Kopelman

Summary

Affiliation: University of East Anglia
Country: UK

Publications

  1. ncbi request reprint Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients
    P Kopelman
    Institute of Health, University of East Anglia, Norwich, UK
    Int J Obes (Lond) 31:494-9. 2007
  2. ncbi request reprint Health risks associated with overweight and obesity
    P Kopelman
    Medical Unit, University of East Anglia, Institute of Health, Norwich, UK
    Obes Rev 8:13-7. 2007
  3. ncbi request reprint Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial. Sibutramine Trial of Obesity Reduction and Maintenance
    D Hansen
    Research Department of Human Nutrition and Centre for Advanced Food Science, LMC, The Royal Veterinary and Agricultural University, Frederiksberg, Denmark
    Int J Obes Relat Metab Disord 25:496-501. 2001
  4. ncbi request reprint Energy metabolism in Bardet-Biedl syndrome
    C Grace
    Obesity Research Department, Royal London Hospital, London, UK
    Int J Obes Relat Metab Disord 27:1319-24. 2003
  5. ncbi request reprint Executive summary: Foresight 'Tackling Obesities: Future Choices' project
    P Kopelman
    Obes Rev 8:vi-ix. 2007

Collaborators

Detail Information

Publications5

  1. ncbi request reprint Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients
    P Kopelman
    Institute of Health, University of East Anglia, Norwich, UK
    Int J Obes (Lond) 31:494-9. 2007
    ..To determine the efficacy, safety and tolerability of cetilistat (ATL-962), a novel inhibitor of gastrointestinal (GI) lipases, in obese patients...
  2. ncbi request reprint Health risks associated with overweight and obesity
    P Kopelman
    Medical Unit, University of East Anglia, Institute of Health, Norwich, UK
    Obes Rev 8:13-7. 2007
  3. ncbi request reprint Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial. Sibutramine Trial of Obesity Reduction and Maintenance
    D Hansen
    Research Department of Human Nutrition and Centre for Advanced Food Science, LMC, The Royal Veterinary and Agricultural University, Frederiksberg, Denmark
    Int J Obes Relat Metab Disord 25:496-501. 2001
    ..As only 8% of the variation in 24 months weight change could be explained by the predictors, the clinical value of this information is limited...
  4. ncbi request reprint Energy metabolism in Bardet-Biedl syndrome
    C Grace
    Obesity Research Department, Royal London Hospital, London, UK
    Int J Obes Relat Metab Disord 27:1319-24. 2003
    ..For BBS, the phenotypic characterisation of the components of energy balance and the implications for their management remains relatively uninvestigated...
  5. ncbi request reprint Executive summary: Foresight 'Tackling Obesities: Future Choices' project
    P Kopelman
    Obes Rev 8:vi-ix. 2007